ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 123 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2017. The put-call ratio across all filers is 2.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $80,000 | +166.7% | 1,348 | +68.1% | 0.00% | – |
Q3 2019 | $30,000 | -21.1% | 802 | -3.0% | 0.00% | – |
Q2 2019 | $38,000 | +15.2% | 827 | 0.0% | 0.00% | – |
Q1 2019 | $33,000 | -31.2% | 827 | -21.0% | 0.00% | – |
Q4 2018 | $48,000 | +336.4% | 1,047 | +349.4% | 0.00% | – |
Q3 2018 | $11,000 | -85.1% | 233 | -77.0% | 0.00% | -100.0% |
Q2 2018 | $74,000 | 0.0% | 1,015 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $74,000 | -26.7% | 1,015 | -33.4% | 0.00% | 0.0% |
Q4 2017 | $101,000 | +27.8% | 1,524 | -2.6% | 0.00% | 0.0% |
Q3 2017 | $79,000 | +61.2% | 1,564 | +49.0% | 0.00% | 0.0% |
Q2 2017 | $49,000 | +58.1% | 1,050 | +18.5% | 0.00% | – |
Q1 2017 | $31,000 | +181.8% | 886 | -1.6% | 0.00% | – |
Q4 2016 | $11,000 | -8.3% | 900 | 0.0% | 0.00% | – |
Q3 2016 | $12,000 | +33.3% | 900 | 0.0% | 0.00% | – |
Q2 2016 | $9,000 | -40.0% | 900 | 0.0% | 0.00% | – |
Q1 2016 | $15,000 | -25.0% | 900 | 0.0% | 0.00% | – |
Q4 2015 | $20,000 | – | 900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
RA Capital Management | 704,701 | $24,883,000 | 3.05% |
Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
FT Options LLC | 22,834 | $806,000 | 1.06% |